<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118933</url>
  </required_header>
  <id_info>
    <org_study_id>K19406-JS001-ISS-141</org_study_id>
    <nct_id>NCT04118933</nct_id>
  </id_info>
  <brief_title>A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer</brief_title>
  <official_title>An Exploratory Study for PD-1 Antibody JS001 in Participants With Microsatellite Instability-high (MSI-H) Advanced or Recurrent Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xu jianmin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the efficacy of PD-1 antibody JS001 in the treatment of participants with
      microsatellite instability-high (MSI-H) advanced or recurrent colorectal cancer, so as to
      provide sufficient evidence for MSI-H as a biomarker of PD-1/PD-L1 inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">July 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>12 Weeks from the drug firstly being taken</time_frame>
    <description>The 12 week objective response will be measured according to RECIST v1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>MSI-H advanced colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS001</intervention_name>
    <description>JS001 240mg, Q3W</description>
    <arm_group_label>MSI-H advanced colorectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fully understand the study and sign informed consent voluntarily;

          -  Histologically confirmed advanced or recurrent colorectal cancer, and MSI detection
             identified MSI-H;

          -  Patients who have previously received first-line or above chemotherapy or targeted
             therapy and failed to the treatment or experienced recurrence;

          -  At least one measurable lesion (RECIST 1.1);

          -  Agree to provide tumor tissue samples and Pathology reports related to the specimens;

          -  Aged 18 to 75 years, gender not limited;

          -  Eastern Cooperative Oncology Group(ECOG) performance status(PS) 0-1; 8. Expected
             survival â‰¥3 months;

          -  Laboratory test values must meet the following standards within 7 days before
             enrollment;

          -  Women of reproductive age must confirm that the serum pregnancy test is negative and
             agree to use effective contraceptive measures during the study drug use

        Exclusion Criteria:

          -  Uncontrolled or symptomatic hypercalcemia;

          -  Had major surgery or had not fully recovered from previous surgery within 4 weeks
             before enrollment;

          -  central nervous system(CNS) metastases;

          -  Bone metastases;

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated
             drainage (once a month or more frequently) allow the patient to have a catheter
             indwelling;

          -  Having a history of idiopathic pulmonary fibrosis, organic pneumonia;

          -  Uncontrolled active infection, including but not limited to acute pneumonia;

          -  Have other malignant tumors at the same time;

          -  The patient has any active autoimmune diseases or a history of autoimmune diseases;

          -  Liver diseases of known clinical significance, including active viral viral hepatitis,
             alcoholic hepatitis or other hepatitis, cirrhosis, fatty liver and hereditary liver
             diseases.

          -  Previous use of anti-PD-1 antibody, anti-PD-l1 antibody, anti-PD-l2 antibody or
             anti-CTLA-4 antibody;

          -  Patients with active tuberculosis (TB);

          -  Received systemic immunosuppressive within 4 weeks prior to day 1 of the first cycle;

          -  Pregnancy test positive;

          -  Known human immunodeficiency virus (HIV) infection;

          -  A history of severe allergy, anaphylaxis or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins;

          -  Those who are known to be allergic to biological drugs produced by hamster ovary cells
             in China, or to citric acid monohydrate, sodium citrate dihydrate, mannitol and
             polysorbate (components of the experimental drugs);

          -  Patients who have previously received allogeneic stem cells or parenchymal organ
             transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Xu, MD</last_name>
    <phone>+8613501984869</phone>
    <email>xujmin@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dexiang Zhu, MD</last_name>
      <phone>+8613764353275</phone>
      <email>shzhudx@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 5, 2019</last_update_submitted>
  <last_update_submitted_qc>October 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xu jianmin</investigator_full_name>
    <investigator_title>Deputy director of the colorectal cancer center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

